CDC issues opioid prescribing guidelines

The Centers for Disease Control and Prevention’s 2016 opioid-prescribing guidelines marked a late federal effort to curb opioid use for chronic pain, but their arrival did not resolve the crisis of how to treat pain safely. The book places them at the intersection of two harms: years of liberal prescribing, and the risk that a broad reaction against opioids would leave some patients without effective care. Their recommendations echoed warnings made years earlier, while their implementation exposed how difficult it was to distinguish prudent limits from abandonment.

The prescribing climate before the guidelines

OxyContin’s 1996 introduction coincided with a medical movement to designate pain as the fifth vital sign. As hospitals and accrediting bodies adopted new standards for assessing and treating pain, patient satisfaction surveys and reimbursement pressures encouraged clinicians to take pain more seriously. In 1999, the Joint Commission on Accreditation of Healthcare Organizations made pain-assessment and treatment standards mandatory. Purdue Pharma saw an opportunity to present itself as a leader in helping hospitals meet those requirements: its budget plan proposed pain-management materials, and its planned promotional goods included $300,000 in branded scroll pens, $225,000 in resource binders, and $290,000 in wall charts and clipboards.

The expansion rested partly on claims that opioid addiction was exceptionally rare when medication was taken as prescribed. Purdue Pharma promoted OxyContin for a broad range of pain, and its representatives framed prescribing it as compassionate care. Yet the definition of adequate pain relief remained unsettled. Pain scales gave subjective reports the appearance of objective measurement; a labor contraction and a stubbed toe could both receive the highest rating, depending on the person’s tolerance. The book notes that reliance on these scales did not correlate with better patient outcomes and was associated with increased opioid prescribing and abuse.

A delayed attempt to change practice

In 2016, the Centers for Disease Control and Prevention announced voluntary prescribing guidelines that strongly recommended limiting opioids for chronic pain. The book emphasizes how long this response had taken: the recommendations echoed, almost word for word, what Barbara Van Rooyan had urged the U.S. Food and Drug Administration to do about a decade earlier. The American Medical Association also took two decades to endorse removing pain as the fifth vital sign from its standards of care. These delays frame the guidelines not as the beginning of concern, but as the arrival of formal caution after years in which pain treatment and opioid prescribing had been encouraged to expand.

The guidance entered a landscape where prescribing remained widespread. The book observes that more than half of patients taking OxyContin were on doses higher than those suggested by the guidelines, even as many patients with legitimate pain believed the pendulum had swung too far in the other direction. The continuing volume of prescriptions also raised a practical question: if three-quarters of opioid prescriptions went unused and could be stolen from medicine cabinets, why did surgeons continue to prescribe so many? The guidelines offered a limit-oriented response, but the scale and persistence of prescribing showed that publication alone could not settle clinical practice.

The costs of an overcorrection

The book illustrates the guidelines’ possible chilling effect through a journalist and former colleague with a sixty-four-degree curve in her lumbar spine and slipped disks that caused severe arthritis pain. Pain medication had enabled her to work and pursue ordinary activities, while helping her avoid risky surgery. Her scoliosis specialist discontinued her pain management without notice or discussion of an alternative strategy, because the new guidance had frightened him into abandoning patients. Her next practitioner required pill counts, lower-dose prescriptions, and more frequent refill visits, increasing her out-of-pocket expenses and making her feel treated with suspicion rather than as a person in pain.

The controversy extended beyond individual treatment decisions. The two employees responsible for drafting the Centers for Disease Control and Prevention guideline received death threats. The episode captures the pressure surrounding a policy meant to reduce harm: patients who depended on opioid medication feared being swept into restrictive practices, while clinicians faced the consequences of prescribing amid a deadly epidemic. The book does not present the guidelines as a simple solution, but as a contested intervention whose broad recommendations could be interpreted more harshly in practice than intended.

Prescribing limits alongside treatment access

The book sets the prescribing debate beside the separate problem of getting people with opioid addiction into sustained care. Kristi Fernandez could not afford to send Jesse Bolstridge promptly to another rehabilitation program after his earlier treatment. That 2013 stay had cost $25,000, which he still owed despite being on his mother’s insurance; he had briefly received buprenorphine and was tapered off after three weeks. Nora Volkow, director of the National Institute on Drug Abuse, later argued that evidence supported long-term medication maintenance with behavioral treatment and recovery support, rather than short detoxification programs aimed at abstinence. This contrast shows that limiting opioid prescribing and providing effective treatment for addiction were related public-health challenges, but not interchangeable policies.

In 2017, the Hope Initiative’s volunteers assembled a five-page spreadsheet of thirty-six rehabilitation and aftercare providers, matching people seeking help to their finances and available beds. Some also helped arrange outpatient medication-assisted treatment, though volunteers disagreed about its effectiveness. Meanwhile, a $1 million grant to Warren Bickel’s Virginia Tech Carilion Research Institute supported a pilot to connect emergency-room overdose patients directly to outpatient buprenorphine, including through a newly approved monthly injection. Yet access remained constrained: Roanoke’s community services board had added treatment for only twenty-one patients, contingent on counseling, and Carilion had a three-week wait for outpatient medication-assisted treatment. These efforts underline the limits of treating the epidemic through prescribing guidance alone. Safer prescribing, adequate pain care, and timely addiction treatment all depended on how policy was translated into available care.